CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 81 enrolled
Drug / intervention
bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01243567
NCT01243567Phase 4Completed
CompareCT.gov

Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated

Allergan·interventional·Posted Nov 18, 2010·Updated Apr 18, 2019

In Brief

A Phase 4 clinical trial evaluating bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution and latanoprost 0.005% ophthalmic solution for Glaucoma, Open-Angle. Completed, enrolled 81 participants across 2 sites in 2 countries.

Detailed Summary

This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk for progression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle
CountriesPortugal, Spain
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2010
Enrollment StartJun 1, 2010
Primary CompletionFeb 14, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.6 years ago

Interventions

bimatoprost 0.03%/timolol 0.5% combination ophthalmic solutiondrug

Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.

latanoprost 0.005% ophthalmic solutiondrug

Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.